8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 25, 2026·SEC
Cytosorbents Corporation(CTSO)Earnings, Financials & Key Ratios
CTSO•NASDAQ
Price updated Jun 19, 2026
AboutCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Show more
- Revenue$37M+4.1%
- EBITDA-$13M+14.3%
- Net Income-$8M+60.4%
- EPS (Diluted)-0.13+65.8%
- Gross Margin71.48%+2.2%
- EBITDA Margin-34.02%+17.7%
- Operating Margin-38.42%+16.9%
- Net Margin-22.12%+62.0%
- ROE-96.39%+20.0%
CTSO Key Insights
Cytosorbents Corporation (CTSO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗High debt to equity ratio of 4.9x
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Shares diluted 14.3% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CTSO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTSO Price & Volume
Cytosorbents Corporation (CTSO) stock price & volume — 10-year historical chart
Loading chart...
CTSO Growth Metrics
Cytosorbents Corporation (CTSO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years24.76%
5 Years-1.24%
3 Years2.23%
TTM5.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM25.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.51%
Return on Capital
10 Years-70.53%
5 Years-45.99%
3 Years-50.66%
Last Year-39.54%
CTSO Recent Earnings
Cytosorbents Corporation (CTSO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.08-33.3%
$0.06
Rev
$9M-5.7%
$9M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.09-80.0%
$0.05
Rev
$9M-5.6%
$10M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.04+33.3%
$0.06
Rev
$9M+2.9%
$9M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.05+28.6%
$0.07
Rev
$10M+4.3%
$9M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.08vs $0.06-33.3% | $9Mvs $9M-5.7% |
| Q2 2026 | Mar 25, 2026 | $0.09vs $0.05-80.0% | $9Mvs $10M-5.6% |
| Q4 2025 | Nov 13, 2025 | $0.04vs $0.06+33.3% | $9Mvs $9M+2.9% |
| Q3 2025 | Aug 7, 2025 | $0.05vs $0.07+28.6% | $10Mvs $9M+4.3% |
Based on last 12 quarters of dataView full earnings history →
CTSO Peer Comparison
Cytosorbents Corporation (CTSO) competitors in Renal, dialysis, and blood purification — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 MASI | 9.42B | 179.95 | -64.27 | -27.1% | 4.9% | 9.08% | 0.78 | |
 ICUI | 3.51B | 140.37 | 4774.49 | -6.38% | 2.15% | 2.19% | 0.66 | |
 LMAT | 2.14B | 93.95 | 37.28 | 13.53% | 24.35% | 16.19% | 0.47 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 BAX | 10.27B | 19.89 | -11.37 | 5.72% | -9.7% | -16.5% | 1.64 | |
 KRMD | 179.14M | 3.90 | -68.30 | 22.23% | -5.27% | -13.61% | 0.21 | |
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 |
Compare CTSO vs Peers
Cytosorbents Corporation (CTSO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTSO Income Statement
Cytosorbents Corporation (CTSO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 13.38M | 20.25M | 22.77M | 39.45M | 40.11M | 34.69M | 31.08M | 35.59M | 37.06M | 37.2M |
Revenue Growth % | 63.07% | 51.34% | 12.41% | 73.3% | 1.66% | -13.51% | -10.39% | 14.51% | 4.12% | 5.29% |
Cost of Goods Sold | 5.52M | 7.49M | 7.36M | 11.05M | 11.05M | 13.96M | 9.13M | 10.71M | 10.57M | 10.79M |
COGS % of Revenue | 41.24% | 36.98% | 32.35% | 28.01% | 27.54% | 40.23% | 29.38% | 30.08% | 28.52% | - |
Gross Profit | 7.86M▲ 0% | 12.76M▲ 62.3% | 15.4M▲ 20.7% | 28.4M▲ 84.4% | 29.06M▲ 2.3% | 20.73M▼ 28.7% | 21.95M▲ 5.9% | 24.89M▲ 13.4% | 26.49M▲ 6.4% | 26.41M▲ 0% |
Gross Margin % | 58.76% | 63.02% | 67.65% | 71.99% | 72.46% | 59.77% | 70.62% | 69.92% | 71.48% | 71.01% |
Gross Profit Growth % | 84.92% | 62.31% | 20.68% | 84.39% | 2.33% | -28.66% | 5.89% | 13.36% | 6.45% | - |
Operating Expenses | 17.71M | 28.35M | 34.38M | 38.77M | 51.81M | 52.25M | 53.9M | 41.34M | 40.73M | 39.81M |
OpEx % of Revenue | 132.31% | 139.97% | 151% | 98.27% | 129.16% | 150.64% | 173.4% | 116.14% | 109.89% | - |
Selling, General & Admin | 15.43M | 22.88M | 24.47M | 31.51M | 38.48M | 2.79M | 38.31M | 33.73M | 35.65M | 35.36M |
SG&A % of Revenue | 115.27% | 112.96% | 107.48% | 79.87% | 95.94% | 8.05% | 123.23% | 94.77% | 96.17% | - |
Research & Development | 4.05M | 7.72M | 12.09M | 8.81M | 16.38M | 15.12M | 15.59M | 7.61M | 5.08M | 4.45M |
R&D % of Revenue | 30.26% | 38.13% | 53.11% | 22.33% | 40.84% | 43.58% | 50.17% | 21.37% | 13.72% | - |
Other Operating Expenses | -1.77M | -2.25M | -2.18M | -1.55M | -3.06M | 34.34M | 0 | 0 | 0 | 0 |
Operating Income | -9.84M▲ 0% | -15.58M▼ 58.3% | -18.97M▼ 21.7% | -10.37M▲ 45.3% | -22.74M▼ 119.3% | -31.52M▼ 38.6% | -31.95M▼ 1.4% | -16.45M▲ 48.5% | -14.24M▲ 13.5% | -13.4M▲ 0% |
Operating Margin % | -73.55% | -76.95% | -83.34% | -26.29% | -56.71% | -90.87% | -102.78% | -46.22% | -38.42% | -36.01% |
Operating Income Growth % | 14.35% | -58.34% | -21.75% | 45.34% | -119.33% | -38.59% | -1.35% | 48.5% | 13.45% | - |
EBITDA | -9.62M | -15.19M | -18.39M | -9.71M | -21.62M | -30.64M | -29.93M | -14.71M | -12.61M | -12.17M |
EBITDA Margin % | -71.92% | -75.03% | -80.79% | -24.61% | -53.89% | -88.33% | -96.27% | -41.32% | -34.02% | -32.71% |
EBITDA Growth % | 15.06% | -57.87% | -21.05% | 47.21% | -122.62% | -41.75% | 2.33% | 50.85% | 14.28% | 14.26% |
D&A (Non-Cash Add-back) | 218.27K | 390.55K | 581.53K | 660.79K | 1.13M | 882.62K | 2.02M | 1.74M | 1.63M | 1.23M |
EBIT | -8.39M | -16.37M | -19.32M | -10.37M | -22.74M | -30.89M | -29.9M | -21.01M | -5.99M | -8.16M |
Net Interest Income | -749.08K | -1.46M | -1.03M | -1.2M | 28.01K | 132.6K | -157.89K | -1.4M | -2.61M | -1.15M |
Interest Income | 0 | 0 | 0 | 0 | 28K | 133K | 0 | 0 | 0 | 0 |
Interest Expense | 749.08K | 1.46M | 1.03M | 1.2M | 0 | 0 | 157.89K | 1.4M | 2.61M | 1.15M |
Other Income/Expense | 705.06K | -2.25M | -1.38M | 1.41M | -2.55M | -2.38M | 1.89M | -5.96M | 5.64M | 1.15M |
Pretax Income | -9.14M▲ 0% | -17.83M▼ 95.1% | -20.36M▼ 14.2% | -8.96M▲ 56.0% | -25.29M▼ 182.2% | -33.91M▼ 34.0% | -30.06M▲ 11.3% | -22.41M▲ 25.5% | -8.6M▲ 61.6% | -12.25M▲ 0% |
Pretax Margin % | -68.28% | -88.04% | -89.42% | -22.72% | -63.07% | -97.74% | -96.7% | -62.96% | -23.2% | -32.93% |
Income Tax | -676.74K | -619.55K | -1.09M | -1.13M | -736K | -1.09M | -813.74K | -1.69M | -401K | -401K |
Effective Tax Rate % | 7.41% | 3.47% | 5.36% | 12.57% | 2.91% | 3.22% | 2.71% | 7.55% | 4.66% | 3.27% |
Net Income | -8.46M▲ 0% | -17.21M▼ 103.4% | -19.27M▼ 11.9% | -7.84M▲ 59.3% | -24.56M▼ 213.4% | -32.81M▼ 33.6% | -29.25M▲ 10.9% | -20.72M▲ 29.2% | -8.2M▲ 60.4% | -11.85M▲ 0% |
Net Margin % | -63.23% | -84.98% | -84.63% | -19.86% | -61.23% | -94.59% | -94.09% | -58.21% | -22.12% | -31.85% |
Net Income Growth % | 29.13% | -103.42% | -11.94% | 59.32% | -213.36% | -33.61% | 10.87% | 29.16% | 60.43% | 25.9% |
Net Income (Continuing) | -8.46M | -17.21M | -19.27M | -7.84M | -24.56M | -32.81M | -29.25M | -20.72M | -8.2M | -11.85M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.31▲ 0% | -0.56▼ 80.6% | -0.60▼ 7.1% | -0.20▲ 66.7% | -0.57▼ 185.0% | -0.75▼ 31.6% | -0.65▲ 13.3% | -0.38▲ 41.5% | -0.13▲ 65.8% | -0.19▲ 0% |
EPS Growth % | 34.04% | -80.65% | -7.14% | 66.67% | -185% | -31.58% | 13.33% | 41.54% | 65.79% | 33.51% |
EPS (Basic) | -0.31 | -0.56 | -0.60 | -0.20 | -0.57 | -0.75 | -0.65 | -0.38 | -0.13 | - |
Diluted Shares Outstanding | 27.61M | 30.72M | 32.26M | 38.82M | 43.36M | 43.57M | 44.66M | 54.43M | 62.23M | 62.74M |
Basic Shares Outstanding | 27.61M | 30.72M | 32.26M | 38.82M | 43.36M | 43.57M | 44.66M | 54.43M | 62.23M | 62.74M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CTSO Balance Sheet
Cytosorbents Corporation (CTSO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 20.74M | 28.26M | 20.9M | 82.45M | 64.3M | 33.76M | 25.7M | 21.6M | 20.63M | 17.76M |
Cash & Short-Term Investments | 17.32M | 22.37M | 12.23M | 71.42M | 52.14M | 22.14M | 14.13M | 3.28M | 6.25M | 4.81M |
Cash Only | 17.32M | 22.37M | 12.23M | 71.42M | 52.14M | 22.14M | 14.13M | 3.28M | 6.25M | 4.81M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 2.21M | 3.94M | 4.47M | 5.16M | 4.52M | 5.66M | 6.06M | 7.32M | 7.55M | 7.15M |
Days Sales Outstanding | 60.17 | 71.07 | 71.62 | 47.73 | 41.16 | 59.61 | 71.12 | 75.06 | 74.35 | 73.27 |
Inventory | 795.66K | 833.13K | 2.11M | 2.67M | 4.77M | 3.46M | 3.68M | 2.73M | 5.28M | 4.48M |
Days Inventory Outstanding | 52.63 | 40.6 | 104.78 | 88.3 | 157.47 | 90.53 | 147.1 | 93.16 | 182.33 | 147.83 |
Other Current Assets | 0 | 0 | -214 | 0 | 2.87M | 2.49M | 1.83M | 8.27M | 1.55M | 1.31M |
Total Non-Current Assets | 3.36M | 4.48M | 6.48M | 7.5M | 25.22M | 29.47M | 27.56M | 25.77M | 23.55M | 22.8M |
Property, Plant & Equipment | 1.4M | 1.73M | 3M | 3.15M | 18.57M | 23.35M | 22.12M | 20.51M | 18.75M | 18.28M |
Fixed Asset Turnover | 9.54x | 11.71x | 7.60x | 12.53x | 2.16x | 1.49x | 1.41x | 1.74x | 1.98x | 1.96x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.23M | 0 |
Intangible Assets | 1.84M | 2.63M | 3.36M | 4.22M | 4.7M | 4.39M | 3.91M | 3.75M | 0 | 0 |
Long-Term Investments | 123.13K | 128.11K | 123.48K | 125.89K | 1.94M | 1.73M | 1.48M | 0 | 1.52M | 3.04M |
Other Non-Current Assets | 123.13K | 0 | 3.48M | 0 | 0 | 0 | -3.65M | 1.51M | 53K | 4.53M |
Total Assets | 24.1M▲ 0% | 32.75M▲ 35.9% | 27.38M▼ 16.4% | 89.95M▲ 228.5% | 89.52M▼ 0.5% | 63.23M▼ 29.4% | 53.26M▼ 15.8% | 47.37M▼ 11.1% | 44.18M▼ 6.7% | 40.56M▲ 0% |
Asset Turnover | 0.56x | 0.62x | 0.83x | 0.44x | 0.45x | 0.55x | 0.58x | 0.75x | 0.84x | 0.83x |
Asset Growth % | 148.65% | 35.86% | -16.38% | 228.49% | -0.48% | -29.37% | -15.77% | -11.06% | -6.73% | -41.33% |
Total Current Liabilities | 7.85M | 6.54M | 9.94M | 10.15M | 13.69M | 9.71M | 14.55M | 9.82M | 9.71M | 16.3M |
Accounts Payable | 1.24M | 1.49M | 2.04M | 2.47M | 2.81M | 1.66M | 3.8M | 3.34M | 2.87M | 3.13M |
Days Payables Outstanding | 82.31 | 72.41 | 101.08 | 81.46 | 92.68 | 43.29 | 151.97 | 113.85 | 99.05 | 105.16 |
Short-Term Debt | 4M | 666.67K | 2.09M | 0 | 570.57K | 108.94K | 2.5M | 0 | 541K | 7.21M |
Deferred Revenue (Current) | 14.75K | 0 | 157.66K | 1.03M | 1.95M | 1.52M | 1.38M | 419.33K | 0 | 561K |
Other Current Liabilities | 1.58M | 479.78K | 200.84K | 0 | 4.31M | 3.55M | 3.15M | 865.51K | 6.3M | 5.96M |
Current Ratio | 2.64x | 4.32x | 2.10x | 8.12x | 4.70x | 3.48x | 1.77x | 2.20x | 2.13x | 1.09x |
Quick Ratio | 2.54x | 4.20x | 1.89x | 7.86x | 4.35x | 3.12x | 1.51x | 1.92x | 1.58x | 0.81x |
Cash Conversion Cycle | 30.48 | 39.26 | 75.33 | 54.57 | 105.95 | 106.85 | 66.24 | 54.37 | 157.63 | 115.95 |
Total Non-Current Liabilities | 5.99M | 9.27M | 14.03M | 581.64K | 13.25M | 18.14M | 15.44M | 26.44M | 28.57M | 22.07M |
Long-Term Debt | 5.99M | 9.27M | 13.39M | 0 | 0 | 5M | 2.54M | 14M | 16.67M | 11.75M |
Capital Lease Obligations | 0 | 1.07M | 642.68K | 581.64K | 13.25M | 13.14M | 12.9M | 12.44M | 11.9M | 24.09M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 3.71M | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.31M |
Total Liabilities | 13.84M | 15.81M | 23.96M | 10.73M | 26.94M | 27.86M | 29.99M | 36.26M | 38.28M | 38.37M |
Total Debt | 9.99M | 9.94M | 16.55M | 1.03M | 13.82M | 18.25M | 18.31M | 26.89M | 29.11M | 18.96M |
Net Debt | -7.33M | -12.43M | 4.32M | -70.39M | -38.32M | -3.89M | 4.18M | 23.61M | 22.86M | 14.15M |
Debt / Equity | 0.97x | 0.59x | 4.84x | 0.01x | 0.22x | 0.52x | 0.79x | 2.42x | 4.93x | 8.64x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.56x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.16x |
Interest Coverage | -11.20x | -11.20x | -18.70x | -8.63x | - | - | -189.39x | -15.02x | -2.29x | -7.09x |
Total Equity | 10.26M▲ 0% | 16.93M▲ 65.0% | 3.42M▼ 79.8% | 79.22M▲ 2217.6% | 62.58M▼ 21.0% | 35.37M▼ 43.5% | 23.28M▼ 34.2% | 11.11M▼ 52.3% | 5.9M▼ 46.9% | 2.19M▲ 0% |
Equity Growth % | 2264.75% | 65.01% | -79.82% | 2217.6% | -21% | -43.47% | -34.2% | -52.28% | -46.85% | -193.15% |
Book Value per Share | 0.37 | 0.55 | 0.11 | 2.04 | 1.44 | 0.81 | 0.52 | 0.20 | 0.09 | 0.03 |
Total Shareholders' Equity | 10.26M | 16.93M | 3.42M | 79.22M | 62.58M | 35.37M | 23.28M | 11.11M | 5.9M | 2.19M |
Common Stock | 28.97K | 31.77K | 32.62K | 43.22K | 43.48K | 43.63K | 54.24K | 54.83K | 63K | 63K |
Retained Earnings | -152.31M | -169.52M | -188.79M | -196.63M | -221.19M | -254M | -282.51M | -304.01M | -312.21M | -317.34M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -360.99K | 288.18K | 525.98K | -1.73M | 525.59K | 2.33M | 529.32K | 4.25M | -2.98M | -2.1M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CTSO Cash Flow Statement
Cytosorbents Corporation (CTSO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.46M | -10.84M | -16.76M | -5.61M | -14.01M | -28.23M | -21.66M | -14.43M | -12.38M | -10.07M |
Operating CF Margin % | -48.28% | -53.52% | -73.61% | -14.23% | -34.92% | -81.39% | -69.66% | -40.53% | -33.39% | - |
Operating CF Growth % | 4.02% | -67.78% | -54.61% | 66.51% | -149.51% | -101.59% | 23.3% | 33.37% | 14.21% | 24.26% |
Net Income | -8.46M | -17.21M | -19.27M | -7.84M | -24.56M | -32.81M | -28.51M | -20.72M | -8.2M | -11.85M |
Depreciation & Amortization | 218.27K | 390.55K | 581.53K | 660.79K | 1.13M | 1.13M | 2.03M | 1.75M | 955K | 926.25K |
Stock-Based Compensation | 3.31M | 0 | 2.84M | 4.71M | 6.2M | 3.8M | 3.7M | 3.76M | 2.77M | 1.95M |
Deferred Taxes | -1.45M | 799.51K | 422.79K | -2.71M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 82.05K | 734.04K | 115.21K | 322.81K | 2.58M | 3.21M | -1.24M | 5.16M | -6.87M | -1.71M |
Working Capital Changes | -160.6K | -937.77K | -1.45M | -757.87K | 641.9K | -3.56M | 2.36M | -4.38M | -1.03M | 613.04K |
Change in Receivables | -649.32K | -1.85M | -642.17K | -326.86K | 420.58K | -1.29M | -245.62K | -1.72M | 423K | 812.89K |
Change in Inventory | 57.32K | -56.75K | -1.28M | -461.51K | -2.35M | 945.35K | -121.04K | 500.47K | -2.54M | -1.62M |
Change in Payables | 523.38K | 1.7M | 470.55K | 1.42T | 2.43M | -3.25M | 1.62M | -1.81M | -706K | -246.72K |
Cash from Investing | -1.68M | -1.52M | -1.52M | -1.68M | -4.28M | -6.46M | -936.24K | -669.43K | -415K | -413.76K |
Capital Expenditures | -1.68M | -1.52M | -1.52M | -1.68M | -4.28M | -6.46M | -936.24K | -669.43K | -164K | -188.76K |
CapEx % of Revenue | 12.54% | 7.51% | 6.68% | 4.25% | 10.67% | 18.61% | 3.01% | 1.88% | 0.44% | 0.51% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -251K | -251K |
Cash from Financing | 20.12M | 17.47M | 8.18M | 66.35M | 715.2K | 4.96M | 14.47M | 9.33M | 9.31M | 2.48M |
Debt Issued (Net) | 5M | 0 | 5M | -15M | 0 | 5M | 0 | 10M | 2.48M | 2.48M |
Equity Issued (Net) | 13.68M | 14.13M | 673.65K | 80.21M | 715.2K | -40.36K | 14.26M | 178.65K | 6.83M | -5.39M |
Dividends Paid | -335.73K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.78M | 3.34M | 2.5M | 1.13M | 0 | 0 | 218.28K | -847.95K | 0 | 5.39M |
Net Change in Cash | 12.08M▲ 0% | 5.05M▼ 58.2% | -10.14M▼ 300.8% | 59.19M▲ 683.9% | -17.6M▼ 129.7% | -29.99M▼ 70.5% | -8.22M▲ 72.6% | -5.85M▲ 28.8% | -1.99M▲ 65.9% | -6.77M▲ 0% |
Free Cash Flow | -8.14M▲ 0% | -12.36M▼ 51.9% | -18.28M▼ 47.9% | -7.29M▲ 60.1% | -18.29M▼ 150.9% | -34.69M▼ 89.7% | -22.59M▲ 34.9% | -14.71M▲ 34.9% | -12.54M▲ 14.8% | -10.2M▲ 0% |
FCF Margin % | -60.82% | -61.03% | -80.29% | -18.48% | -45.59% | -100% | -72.68% | -41.33% | -33.84% | -27.42% |
FCF Growth % | -11.09% | -51.86% | -47.89% | 60.12% | -150.87% | -89.7% | 34.88% | 34.88% | 14.76% | 25.28% |
FCF per Share | -0.29 | -0.40 | -0.57 | -0.19 | -0.42 | -0.80 | -0.51 | -0.27 | -0.20 | -0.16 |
FCF Conversion (FCF/Net Income) | 0.76x | 0.63x | 0.87x | 0.72x | 0.57x | 0.86x | 0.74x | 0.70x | 1.51x | 0.86x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -506.25K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CTSO Key Ratios
Cytosorbents Corporation (CTSO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -172.87% | -126.56% | -189.32% | -18.97% | -34.64% | -67% | -99.73% | -120.52% | -96.39% | -165.13% |
Return on Invested Capital (ROIC) | -694.61% | -314.21% | -232.47% | -93.94% | -103.12% | -84.82% | -81.31% | -39.69% | -33.64% | -39.34% |
Gross Margin | 58.76% | 63.02% | 67.65% | 71.99% | 72.46% | 59.77% | 70.62% | 69.92% | 71.48% | 71.01% |
Net Margin | -63.23% | -84.98% | -84.63% | -19.86% | -61.23% | -94.59% | -94.09% | -58.21% | -22.12% | -31.85% |
Debt / Equity | 0.97x | 0.59x | 4.84x | 0.01x | 0.22x | 0.52x | 0.79x | 2.42x | 4.93x | 8.64x |
Interest Coverage | -11.20x | -11.20x | -18.70x | -8.63x | - | - | -189.39x | -15.02x | -2.29x | -7.09x |
FCF Conversion | 0.76x | 0.63x | 0.87x | 0.72x | 0.57x | 0.86x | 0.74x | 0.70x | 1.51x | 0.86x |
Revenue Growth | 63.07% | 51.34% | 12.41% | 73.3% | 1.66% | -13.51% | -10.39% | 14.51% | 4.12% | 5.29% |
Related:CTSO Dividend History·CTSO Revenue History·CTSO Price History·CTSO P/E History·CTSO Financial Ratios·CTSO Institutional Holders
CTSO SEC Filings & Documents
Cytosorbents Corporation (CTSO) SEC filings — annual & quarterly reports (10-K, 10-Q)
CTSO Frequently Asked Questions
Cytosorbents Corporation (CTSO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cytosorbents Corporation (CTSO) reported $37.2M in revenue for fiscal year 2025. This represents a 371900% increase from $0.0M in 2005.
Cytosorbents Corporation (CTSO) grew revenue by 4.1% over the past year. Growth has been modest.
Cytosorbents Corporation (CTSO) reported a net loss of $11.8M for fiscal year 2025.
Dividend & Returns
Cytosorbents Corporation (CTSO) has a return on equity (ROE) of -96.4%. Negative ROE indicates the company is unprofitable.
Cytosorbents Corporation (CTSO) had negative free cash flow of $10.2M in fiscal year 2025, likely due to heavy capital investments.